A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs IFX 1 (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms SHINE
- Sponsors InflaRx
- 08 Mar 2018 According to an InflaRx media release, company today announced that the first patient has been enrolled in this study.
- 08 Mar 2018 Status changed from planning to recruiting, according to an InflaRx media release.
- 09 Jan 2018 According to an InflaRx media release, Prof. Dr. med. Evangelos J. Giamarellos-Bourboulis at the ATTIKON University Hospital in Athens, Greece is the principal investigator for this study.